mutLBSgeneDB |
Gene summary for ELK1 |
Gene summary |
Basic gene Info. | Gene symbol | ELK1 |
Gene name | ELK1, member of ETS oncogene family | |
Synonyms | - | |
Cytomap | UCSC genome browser: Xp11.2 | |
Type of gene | protein-coding | |
RefGenes | NM_001114123.2, NM_001257168.1,NM_005229.4, | |
Description | ETS domain-containing protein Elk-1ETS-like gene 1tyrosine kinase (ELK1) oncogene | |
Modification date | 20141207 | |
dbXrefs | MIM : 311040 | |
HGNC : HGNC | ||
Ensembl : ENSG00000126767 | ||
HPRD : 02407 | ||
Vega : OTTHUMG00000021452 | ||
Protein | UniProt: P19419 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_ELK1 | |
BioGPS: 2002 | ||
Pathway | NCI Pathway Interaction Database: ELK1 | |
KEGG: ELK1 | ||
REACTOME: ELK1 | ||
Pathway Commons: ELK1 | ||
Context | iHOP: ELK1 | |
ligand binding site mutation search in PubMed: ELK1 | ||
UCL Cancer Institute: ELK1 | ||
Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO Term | PubMed ID | GO:0045893 | positive regulation of transcription, DNA-templated | 15790681 | GO:0045944 | positive regulation of transcription from RNA polymerase II promoter | 12750007 |
Top |
Ligand binding site mutations for ELK1 |
Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.) : non-synonymous mutation on LBS, Circle size denotes number of samples. |
Cancer type specific mutLBS sorted by frequency |
LBS | AAchange of nsSNV | Cancer type | # samples | K50 | R49C | BRCA | 1 | R62 | A63V | STAD | 1 | K59 | L60F | UCEC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for ELK1 |
Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
: nsSNV at non-LBS: nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | K59 | L60F | -1.1025689 | K50 | R49C | -0.5309184 | R62 | A63V | -0.41916403 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
Structure image for ELK1 from PDB |
Top |
Differential gene expression and gene-gene network for ELK1 |
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
Top |
Top |
Phenotype information for ELK1 |
Gene level disease information (DisGeNet) |
Disease ID | Disease name | # PubMed | Association type |
Mutation level pathogenic information (ClinVar annotation) |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for ELK1 |
Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
Drug information targeting mutLBSgene (Approved drugs only) |
Drug status | DrugBank ID | Name | Type | Drug structure |
Gene-centered ligand-gene interaction network |
Ligands binding to mutated ligand binding site of ELK1 go to BioLip |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | NUC | Nucleic Acids | 1dux | C | K50 K59 R62 | NUC | Nucleic Acids | 1dux | F | K50 K59 R62 | NUC | Nucleic Acids | 1dux | C | R62 | NUC | Nucleic Acids | 1dux | F | R62 |
Top |
Conservation information for LBS of ELK1 |
Multiple alignments for P19419 in multiple species |
LBS | AA sequence | # species | Species | D58 | TNMNYDKLSRA | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F81 | VSGQKFVYKFV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | K50 | LWGLRKNKTNM | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | K52 | GLRKNKTNMNY | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | K59 | NMNYDKLSRAL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | K75 | KNIIRKVSGQK | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | K80 | KVSGQKFVYKF | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L7 | DPSVTLWQFLL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | M55 | KNKTNMNYDKL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | R62 | YDKLSRALRYY | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | R65 | LSRALRYYYDK | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | T6 | MDPSVTLWQFL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | W46 | EVARLWGLRKN | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Y57 | KTNMNYDKLSR | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Y66 | SRALRYYYDKN | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Y67 | RALRYYYDKNI | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Y68 | ALRYYYDKNII | 3 | Homo sapiens, Mus musculus, Rattus norvegicus |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |